Probiotix Health PLC New appointment
January 31 2024 - 1:00AM
RNS Regulatory News
RNS Number : 4172B
Probiotix Health PLC
31 January 2024
ProBiotix Health
plc
("ProBiotix" or the
"Company")
New appointment
ProBiotix Health plc (AQUIS: PBX), a
life sciences
business developing probiotics to support
cardiometabolic health, announces that Mads
Brandt has joined the Company as Global Supply Chain Director.
Mads's appointment became effective from 1 December 2023, and is
part of the Company's strategy to bring experts on board to support
the future growth plans for the Company.
Mads has over 20 years' experience
in working in the supply chain space, and has a broad understanding
of logistics, management consultancy and operations. He is driven
by his leadership skills and vast expertise in the
medical device, pharma and
medtech industries. He has previously worked for a number of
global organisations such as ISS A/S, PA Consulting Group and LEO
Pharma where he held various key senior management
positions.
Steen
Andersen, CEO of ProBiotix Health plc commented: "On behalf of the team at ProBiotix, I
would like to welcome Mads as our new Global Supply Chain Director
and I know he will be a great asset to the Company. He brings an
extensive skillset in the supply chain field, which can help
greatly in supporting operational, tactical and strategical aspects
of operations at a global scale.
"With his
considerable experience, he can help us to build and optimise our
supply chain, improve on and capitalise on our partnerships with
existing and potentially new CMO's, creating an agile and stable
supply chain to create a platform for growth and help us to plan
our future with efficiency. He will allow us to be even more
innovative in our approach to product solutions to cater for our
customer and market needs."
For further
information, please contact:
ProBiotix Health plc
|
https://probiotixhealth-ir.com/
|
Steen Andersen, Chief
Executive
|
Contact via Walbrook
below
|
|
|
Peterhouse
Capital Limited (Aquis Corporate Adviser and
Broker)
|
Tel: 020 7469
0930
|
Mark Anwyl
|
|
Duncan Vasey
|
|
|
|
Walbrook PR Ltd
|
probiotix@walbrookpr.com
|
Anna Dunphy
|
Mob: 07876
741 001
|
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside
information for the purposes of Article 7 of the Market Abuse
Regulation EU 596/2014 as it forms part of retained EU law (as
defined in the European Union (Withdrawal) Act 2018).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NEXKZGFMKGLGDZM
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Nov 2023 to Nov 2024